New hope for Hard-to-Treat lymphoma: drug cocktail enters human trials
NCT ID NCT07159906
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) in 62 adults with relapsed or refractory diffuse large B-cell lymphoma. The goal is to find the safest dose and see if the combo can shrink tumors. It's an early-phase trial, so results will guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Homoharringtonine, Lisaftoclax (BCL-2 inhibitor), Rituximab, and Prednisone
- What this could lead to
- If this works, it could offer a new treatment option for people with hard-to-treat lymphoma who have run out of standard therapies.
- What could go wrong
- This is an early-phase trial with only 62 people, so it's too soon to know if the combination is safe or effective. Side effects from the drugs could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a Light-Based device spot dangerous infection risk without a blood draw?